Pharmacological control of CAR T cells through CRISPR-driven rapamycin resistance

Sébastien Levesque,Gillian Carleton,Victoria Duque,Claudia Goupil,Jean-Philippe Fiset,Sarah Villeneuve,Eric Normandeau,Geneviève Morin,Nellie Dumont,Brad H. Nelson,Josée Laganière,Brian Boyle,Julian J. Lum,Yannick Doyon

DOI: https://doi.org/10.1101/2023.09.14.557485

2024-02-05

Abstract:Chimeric antigen receptors (CARs) reprogram T cells to recognize and target cancer cells. Despite remarkable responses observed with CAR-T cell therapy in patients with hematological malignancies, CAR-T cell engineering still relies mostly on randomly integrating vectors, limiting the possibilities of fine-tuning T cell function. Here, we designed a CRISPR-based marker-free selection strategy to simultaneously target a therapeutic transgene and a gain-of-function mutation to the locus to enrich cells resistant to rapamycin, a clinically used immunosuppressant. We readily engineered rapamycin-resistant (RapaR) CAR-T cells by targeting CAR expression cassettes to the locus. Using cytotoxicity assays, and a humanized mouse model of acute lymphoblastic leukemia, we show that RapaR-CAR-T cells can efficiently target CD19 leukemia cells in presence of immunosuppressing doses of rapamycin. Furthermore, our strategy allows multiplexed targeting of rapamycin-regulated immunoreceptors complexes (DARICs) to the and loci to pharmacologically control CAR-T cells’ activity. We foresee that our approach could both facilitate the enrichment of CRISPR-engineered CAR-T cells and while improving tumor eradication.

Cancer Biology

What problem does this paper attempt to address?

The main problem that this paper attempts to solve is to introduce rapamycin resistance in CAR T cells through CRISPR technology, in order to achieve pharmacological control of CAR T cell functions and improve their anti - tumor activities. Specifically:

1. **Optimization of CAR T cell functions**: CAR T cell therapy has achieved remarkable results in the treatment of hematological malignancies. However, current CAR T cell engineering mainly relies on randomly integrating vectors, which limits the fine - tuning of T cell functions. The paper proposes a CRISPR - based marker - free selection strategy, simultaneously targeting therapeutic transgenes and a gain - of - function mutation to the MTOR locus, thereby enriching cells resistant to rapamycin.

2. **Introduction of rapamycin resistance**: Rapamycin is a commonly used immunosuppressant in clinical practice. By introducing rapamycin - resistant mutations (such as F2108L) at the MTOR locus, researchers were able to design CAR T cells resistant to rapamycin (RapaR - CAR - T cells). These cells can still effectively kill CD19 - positive leukemia cells in the presence of rapamycin.

3. **Pharmacological control of CAR T cell activity**: Further, the research team explored how to achieve pharmacological control of CAR T cell activity by multi - targeting rapamycin - regulated immune receptor complexes (DARICs) to the MTOR and TRAC loci. This method can not only enrich CRISPR - edited CAR T cells in vitro and in vivo, but also regulate the activity of CAR T cells through the use of rapamycin, thereby improving the efficiency of tumor eradication.

4. **Potential for clinical application**: The paper demonstrated the application effect of this strategy in a humanized mouse acute lymphoblastic leukemia model, proving that RapaR - CAR - T cells can more effectively control tumor progression in the presence of rapamycin. In addition, by introducing DARICs, researchers were also able to activate CAR T cells at immunosuppressive doses of rapamycin, further improving the flexibility and safety of treatment.

In summary, this paper aims to optimize the functions of CAR T cells and improve their efficacy and safety in clinical applications through the introduction of rapamycin resistance and pharmacological control mechanisms by CRISPR technology.